Salix Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R)
LAVAL, QC / ACCESSWIRE / February 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the opening of the 2024 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals.
Salix Pharmaceuticals is partnering with two advocacy groups to establish a first-ever opioid-induced constipation (OIC) awareness day to help dispel the stigma and silence around the condition.
Salix Pharmaceuticals is putting a new date in the disease awareness calendar. Working with two nonprofits, the drugmaker has declared Dec. 5 Opioid-Induced Constipation (OIC) Awareness Day to try to tackle the stigma and silence surrounding this condition.
Bausch Health’s gastroenterology unit Salix Pharmaceuticals has chalked up a win in its long-running fight to fend off a generic to its irritable bowel syndrome diarrhea (IBD-D) med Xifaxan.
LAVAL, QC / ACCESSWIRE / October 10, 2023 / Salix Pharmaceuticals, the gastroenterology business of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today released the Salix Liver Health Trends Report, Third Edition, which documents the evolving crisis of chronic liver disease (CLD), showing a 9% increase in CLD and cirrhosis mortality marking these as the ninth leading cause of death in the United States in 2021. The report, based on a survey of 400 health care providers (HCPs) who treat CLD, qualitative interviews with HCPs and secondary research from peer-reviewed publications, also stresses the ongoing disparities and gaps in CLD care that affect different populations and geographies, including a shortage of liver specialists in rural areas.
When actor Bellamy Young was growing up, her father suffered from a brain disorder called hepatic encephalopathy (HE) caused by cirrhosis of the liver.
LAVAL, QC / ACCESSWIRE / October 4, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced its partnership with award-winning actor Bellamy Young, who is speaking out to help educate people who are impacted by hepatic encephalopathy (HE), caused by cirrhosis. Bellamy wants those affected to know they are not alone and to help them overcome stigma that can interfere with disease education.
LAVAL, QC / ACCESSWIRE / July 11, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced the winners of its 2023 Salix Gastrointestinal Health Scholars Program. For the fourth consecutive year, Salix will be awarding $10,000 each to 10 students living with a GI disease.
LAVAL, QC / ACCESSWIRE / June 19, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced its presence at the European Association for the Study of the Liver (EASL) Congress 2023. XIFAXAN® (rifaximin) data was selected for inclusion in the Cirrhosis and its complication's session. EASL Congress 2023 will be held virtually and in-person in Vienna, Austria, from June 21-24, 2023.